Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines

Quiambao, Beatriz P.; Ambas, Cristina; Diego, Sherylle; Castells, Valérie Bosch; Korejwo, Joanna; Petit, Céline; Rasuli, Anvar; Houillon, G

doi:10.1016/j.vaccine.2020.03.043

Cited by 6 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The category II/III patients (4-site booster) achieved a robust anamnestic response (100% seroconversion rates with GMTs ranging from 137 to 193 IU/mL at day 11 post-booster). However, the relative attenuation of RVNA titers with ERIG appears to persist with the booster [31].…”

Section: Booster Responsementioning

confidence: 97%

“…There were 26 citations identified that reported immunogenicity data following ID PVRV as part of PEP [25,26,28,; of these 14 studies were undertaken in Thailand [25,28,30,[32][33][34]37,39,42,44,[46][47][48]51], and 5 in India [35,36,38,43,45]. Three studies were undertaken in The Philippines [40,50,52], and one included long-term follow up to year 5 [31,50]. The remainder were undertaken in Lithuania, the UK, and Cambodia [41,49,53].…”

Section: Immunogenicity Of Pep Regimensmentioning

confidence: 99%

“…One randomized controlled study reported persistence of PEP immunogenicity annually from year 1 to 5 post-vaccination [31,50]. Seroconversion rates remained >95% in the group that received the shortened 1-week 4-site ID (4-4-4-0-0) regimen with PVRV.…”

Section: Persistence Of Pep Immunogenicitymentioning

confidence: 99%

“…Four studies assessed PEP followed by simulated (booster) PEP after 1 year [36,37,40] or 5 years [31]. Of these, two studies assessed simulated PEP in otherwise healthy participants after 1 year [36,37].…”

Section: Booster Responsementioning

confidence: 99%

“…In the second study, 100% seroconversion rate was reported at day 14 after initiation of booster (0, 3 [1-1] regimen) and the GMT was 15.12 IU/mL [37]. The other two studies assessed simulated PEP after at least 1 year (mean 419 days) and at 5 years following prophylaxis for category I/II [40] or II/III [31] exposure, respectively. In category I/II patients (1-site booster), 100% seroconversion rate was achieved by day 14 post-booster and the GMT was >10 IU/mL [40].…”

Section: Booster Responsementioning

confidence: 99%

See 4 more Smart Citations

Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

et al. 2020

Self Cite

View full text Add to dashboard Cite

The purified Vero cell rabies vaccine (PVRV; Verorab ® , Sanofi Pasteur) has been used in rabies prevention since 1985. Evolving rabies vaccination trends, including shorter intradermal (ID) regimens with reduced volume, along with WHO recommendation for ID administration has driven recent ID PVRV regimen assessments. Thus, a consolidated review comparing immunogenicity of PVRV ID regimens during pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) is timely and beneficial in identifying gaps in current research. A search of seven databases for studies published from 1985 to November 2019 identified 35 studies. PrEP was assessed in 10 studies (n = 926) with 1-3-site, 1-3-visit regimens of up to 3-months duration. Seroconversion (rabies virus neutralizing antibodies [RVNA] ≥ 0.5 IU/mL) rates of 90-100% were reported within weeks, irrespective of regimen, with robust booster responses at 1 year (100% seroconversion rates by day 14 post-booster). However, data are lacking for the current WHO-recommended, 2-site, 1-week ID PrEP regimen. PEP was assessed in 25 studies (n = 2136) across regimens of 1-week to 90-day duration. All ID PEP regimens assessed induced ≥ 99% seroconversion rates (except in HIV participants) by day 14-28. This review confirms ID PVRV suitability for rabies prophylaxis and highlights the heterogeneity of use in the field.

show abstract

Section: Booster Responsementioning

confidence: 97%

Section: Immunogenicity Of Pep Regimensmentioning

confidence: 99%

Section: Persistence Of Pep Immunogenicitymentioning

confidence: 99%

Section: Booster Responsementioning

confidence: 99%

Section: Booster Responsementioning

confidence: 99%

See 3 more Smart Citations

Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Human rabies: prospects for elimination

et al. 2021

View full text Add to dashboard Cite

Almost half of all countries in the world are effectively free of human deaths from dog-mediated rabies. But the disease still affects people in low- and middle-income countries, especially the rural poor, and children. Successful regional elimination of human rabies is attributable to advances in significant and sustained investment in dog vaccination, post-exposure vaccination and surveillance, illustrated by productive efforts to reduce human rabies in Latin America over the last 35 years. Nonetheless, countries still facing endemic rabies face significant barriers to elimination. Using the 2017 Global Strategic Plan to end human rabies deaths from dog-mediated rabies by 2030 as a reference point and an organizing framework, we assess progress toward global rabies elimination by examining the characteristics of successful regional control efforts and barriers to elimination. Although substantive barriers exist for countries where rabies remains endemic, advances in knowledge, technology, institutions, and economics provide a basis for optimism.

show abstract

Modern biologics for rabies prophylaxis and the elimination of human cases mediated by dogs

Tantawichien

Rupprecht²

2020

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines

Cited by 6 publications

References 20 publications

Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

Human rabies: prospects for elimination

Modern biologics for rabies prophylaxis and the elimination of human cases mediated by dogs

Contact Info

Product

Resources

About